Although I understand that Amarin has stated that it intends to complete the REDUCE-IT trial, it is conceivable that Amarin might choose to forego the trial should it prevail in this lawsuit. Were that to happen, the medical and scientific community would be deprived of the robust scientific data promised by the REDUCE-IT trial regarding the safety and efficacy of Vascepa for the use related to cardiovascular disease.
You mean that important trial that you promised AMRN the ANCHOR indication when 50% enrolled so they could pay for it's completion, then yanked it away? That one? And you think AMRN would cancel it, foregoing billions in on label sales, if they win the suit? Is that a joke?